oncology

Phoenix Asia Holdings ($PHOE) surged 47% after-hours following $1B deal to acquire ACEA Pharma, pivoting from construction into oncology and autoimmune drug development.

Roche to acquire digital pathology company PathAI for up to $1.05 billion, paying $750 million upfront with $300 million in milestone payments to strengthen AI diagnostics capabilities.

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.

Pfizer beats Q1 2026 expectations with $0.75 EPS and $14.45B in sales. Patent settlement extends Vyndamax protection to June 2031, ensuring revenue stability.

FDA approves VEPPANU, first PROTAC therapy for advanced breast cancer with ESR1 mutations, showing 43% reduction in disease progression risk versus existing treatment.

AstraZeneca's prostate drug Truqap wins FDA panel backing (7-1 vote) for PTEN-deficient tumors, but breast cancer candidate camizestrant rejected despite superior efficacy data.

Telix's next-gen prostate cancer therapy shows reduced organ toxicity in Phase 2 trial, expanding into earlier-stage disease applications with expanded clinical potential.

AstraZeneca ($AZN) reported Q1 revenue of $15.29B, up 13% YoY, with oncology surging 20%. Shares fell 2.30% despite beating estimates.

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.

Celcuity rises 4% after Citizens initiates 'market outperform' coverage with $150 price target, citing gedatolisib's breast cancer approval potential within two months and multi-indication opportunity.

Compass Therapeutics to present Phase 2/3 data on tovecimig for biliary tract cancer on April 27, 2026, with 80% overall survival events achieved.

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

Ascentage Pharma selected for six abstracts at ASCO 2026, including three rapid oral presentations featuring data on three key oncology drug candidates.

Bispecific antibody drug conjugates market projected at $2B+ by 2030, with first approval expected by 2028 amid 150+ global clinical trials.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Peptide drug conjugate market projected to reach $1.5 billion by 2031 with 14%+ CAGR, driven by targeted oncology therapies and innovative linker technologies from major biotech players.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

Legend Biotech surges 18% on bullish analyst upgrades and momentum from Eli Lilly's $7B CAR-T acquisition, with CD19/CD20 therapy driving investor enthusiasm.